MXPA05005178A - Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg). - Google Patents

Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg).

Info

Publication number
MXPA05005178A
MXPA05005178A MXPA05005178A MXPA05005178A MXPA05005178A MX PA05005178 A MXPA05005178 A MX PA05005178A MX PA05005178 A MXPA05005178 A MX PA05005178A MX PA05005178 A MXPA05005178 A MX PA05005178A MX PA05005178 A MXPA05005178 A MX PA05005178A
Authority
MX
Mexico
Prior art keywords
lys
peg
pegylated
pegylated interferon
interferon alfa
Prior art date
Application number
MXPA05005178A
Other languages
English (en)
Spanish (es)
Inventor
Weyer Karl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA05005178A publication Critical patent/MXPA05005178A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA05005178A 2002-11-15 2003-11-10 Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg). MXPA05005178A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02025585 2002-11-15
PCT/EP2003/012498 WO2004045648A1 (en) 2002-11-15 2003-11-10 Positional isomers of peg ifn alpha 2a

Publications (1)

Publication Number Publication Date
MXPA05005178A true MXPA05005178A (es) 2005-07-22

Family

ID=32319537

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05005178A MXPA05005178A (es) 2002-11-15 2003-11-10 Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg).

Country Status (23)

Country Link
US (1) US20040223950A1 (ja)
EP (1) EP1562634B1 (ja)
JP (1) JP4279258B2 (ja)
KR (1) KR20050065677A (ja)
CN (1) CN1323722C (ja)
AR (1) AR042039A1 (ja)
AT (1) ATE337017T1 (ja)
AU (1) AU2003293668A1 (ja)
BR (1) BR0316227A (ja)
CA (1) CA2503594C (ja)
DE (1) DE60307881T2 (ja)
ES (1) ES2270152T3 (ja)
GT (1) GT200300244A (ja)
MX (1) MXPA05005178A (ja)
NO (1) NO20052310L (ja)
PA (1) PA8587801A1 (ja)
PE (1) PE20040834A1 (ja)
PL (1) PL376883A1 (ja)
RU (1) RU2005118752A (ja)
TW (1) TW200413404A (ja)
UY (1) UY28080A1 (ja)
WO (1) WO2004045648A1 (ja)
ZA (1) ZA200503756B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
NZ540043A (en) * 2002-11-18 2007-11-30 Maxygen Inc Isolated or recombinant Interferon-alpha polypeptides and conjugates
JP4896745B2 (ja) 2004-02-02 2012-03-14 アンブレツクス・インコーポレイテツド 修飾されたヒトインターフェロンポリペプチドおよびこれらの使用
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
WO2005113592A2 (en) * 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
WO2007044083A2 (en) 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
JP2008543943A (ja) * 2005-06-20 2008-12-04 ペプゲン コーポレイション ヒトインターフェロンアルファ類似体とインターフェロンタウの低毒性長期循環性キメラ
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CN101002944B (zh) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
CN101636411B (zh) * 2007-09-04 2013-01-09 厦门伯赛基因转录技术有限公司 聚乙二醇修饰的干扰素α2a及其制备方法和应用
ES2382124T3 (es) * 2007-09-04 2012-06-05 Biosteed Gene Expression Tech. Co., Ltd. Interferón alfa 2b modificado con polietilenglicol y método de preparación y aplicaciones de este
PL2272875T3 (pl) * 2008-04-03 2014-06-30 Biosteed Gene Expression Tech Co Ltd Hormon wzrostu modyfikowany dwuniciowym glikolem polietylenowym, sposoby otrzymywania i stosowania
PT2279007T (pt) 2008-04-29 2016-08-23 Ascendis Pharma Growth Disorders Div As Compostos recombinantes e peguilados da hormona de crescimento humana
EP2113256A1 (en) 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
DE102009009344B4 (de) * 2009-02-05 2018-01-04 Helmholtz-Zentrum Dresden - Rossendorf E.V. Verfahren und Anordnung zur Reinigung des Reaktionsgemisches bei der Herstellung von Radiopharmaka
JP5576928B2 (ja) * 2009-03-27 2014-08-20 ジェイダブリュ ファーマシューティカル コーポレーション インターフェロン−アルファ及び細胞質残留性細胞膜透過ペプチドを含むIFN−α融合タンパク質
CN101514229B (zh) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物
WO2016079302A1 (en) 2014-11-21 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Long-acting growth hormone dosage forms
CN106749608B (zh) * 2015-11-18 2021-10-15 石药集团中奇制药技术(石家庄)有限公司 干扰素α缀合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
MXPA05002476A (es) * 2002-09-05 2005-10-19 Gi Company Inc Asialo-interferones modificados y sus usos.

Also Published As

Publication number Publication date
CN1323722C (zh) 2007-07-04
JP2006515571A (ja) 2006-06-01
ZA200503756B (en) 2008-02-27
NO20052310L (no) 2005-08-09
WO2004045648A1 (en) 2004-06-03
ES2270152T3 (es) 2007-04-01
EP1562634A1 (en) 2005-08-17
CN1711109A (zh) 2005-12-21
CA2503594A1 (en) 2004-06-03
DE60307881D1 (de) 2006-10-05
ATE337017T1 (de) 2006-09-15
NO20052310D0 (no) 2005-05-11
TW200413404A (en) 2004-08-01
CA2503594C (en) 2011-05-10
DE60307881T2 (de) 2007-03-08
PE20040834A1 (es) 2004-11-17
EP1562634B1 (en) 2006-08-23
PL376883A1 (pl) 2006-01-09
AR042039A1 (es) 2005-06-08
AU2003293668A1 (en) 2004-06-15
KR20050065677A (ko) 2005-06-29
GT200300244A (es) 2004-06-03
RU2005118752A (ru) 2006-02-10
UY28080A1 (es) 2004-05-31
JP4279258B2 (ja) 2009-06-17
BR0316227A (pt) 2005-10-04
PA8587801A1 (es) 2004-09-16
US20040223950A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
CA2503594C (en) Positional isomers of peg ifn alpha 2a
Foser et al. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a (PEGASYS)
RU2485134C2 (ru) Интерферон альфа 2в, модифицированный полиэтиленгликолем, получение препарата и его применение
AU739359B2 (en) Improved interferon polymer conjugates
JP2008509889A (ja) ペグ化インターフェロンα−1b
KR101483814B1 (ko) 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2a, 이의 합성 방법 및 용도
US5290920A (en) Method of purifying human epidermal growth factor
RU2575796C9 (ru) Пегилированный конъюгат варианта рекомбинантного консенсусного интерферона и способ его получения, и применение
RU2575796C2 (ru) Пегилированный конъюгат варианта рекомбинантного консенсусного интерферона и способ его получения, и применение
EP3323825A1 (en) Polypeptide compound and preparation method and use thereof
HOSOI et al. Structural characterization of fibroblast human interferon-β1
Son et al. Structural identification and biological activity of positional isomers of long-acting and mono-PEGylated recombinant human granulocyte colony-stimulating factor with trimeric-structured methoxy polyethylene glycol N-hydroxysuccinimidyl functional group
Santana et al. Molecular characterization of recombinant human interferon alpha-2b produced in Cuba
Fee Protein conjugates purification and characterization
CN112694526B (zh) 一种白细胞介素29突变体蛋白
CN113286806A (zh) 治疗压力、免疫反应和中风综合征的多肽